Old Web
English
Sign In
Acemap
>
authorDetail
>
Carolyn Brady
Carolyn Brady
Cross Cancer Institute
Breast cancer
Letrozole
Oncology
Internal medicine
Medicine
4
Papers
993
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
L etrozole I s M ore E ffective N eoadjuvant E ndocrine Therapy T han T amoxifen f or E rbB-1- a nd/or ErbB-2-Positive, E strogen R eceptor-Positiv e P rimary Breast C ancer: E vidence F rom a P hase I II Randomized T rial
2001
Matthew J. Ellis
Andrew Coop
Baljit Singh
L. Mauriac
Antonio Llombert-Cussac
William R. Miller
Dean B. Evans
Margaret Dugan
Carolyn Brady
Erhard Quebe-Fehling
Mieke Borgs
Show All
Source
Cite
Save
Citations (0)
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001
Journal of Clinical Oncology
Matthew J. Ellis
Andrew Coop
Baljit Singh
L. Mauriac
Antonio Llombert-Cussac
F. Jänicke
W.R. Miller
Dean B. Evans
Margaret Dugan
Carolyn Brady
Erhard Quebe-Fehling
Mieke Borgs
Show All
Source
Cite
Save
Citations (985)
Letrozole in Second-Line Therapy of Advanced Breast Cancer: More Questions Than Answers
2001
Journal of Clinical Oncology
John R. Mackey
Anil A. Joy
Aman U. Buzdar
Carolyn Brady
Hilary A. Chaudri-Ross
Show All
Source
Cite
Save
Citations (2)
Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer
2001
European Journal of Cancer
Matthew J. Ellis
B. Sing
W.R. Miller
Antonio Llombart-Cussac
F. Jänicke
Dean B. Evans
Mieke Borgs
Erhard Quebe-Fehling
Carolyn Brady
Margaret Dugan
Andrew Coop
Show All
Source
Cite
Save
Citations (6)
1